Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Form 8.3 - Dowlais Group plc
-
Prepayments (CK93) - Totalkredit A/S
-
Prepayments (CK93) - Nykredit Realkredit A/S
-
TRESU Investment Holding A/S – Settlement of interest payment by issuance of interest bonds
-
Share buyback programme – week 25
-
Børsmeddelelse: Børsprospekt samt meddelelse om formue og antal investorer i andelsklasserne Horizon3 Innovation Akk., kl n og Hammers Fonde - Forsvar, kl n under Investeringsforeningen PortfolioMan
-
Suspension i forbindelse med fusion
-
Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine
-
Meddelelse om ændring i porteføljeforvaltningshonorar – I&T Globale Aktier ESG Select
-
Offentliggørelse af prospekt, Investeringsforeningen SEBinvest
-
EveLab Insight Debuts Dynamic Wrinkle Detection Technology at VivaTech 2025, Shaping the Future of AI-Powered Skin Wellness
-
Share repurchase programme: Transactions of week 25 2025
-
WySE Products Launches Total Pet Kitchen, The First-of-Its-Kind Multicooker for Fresh Pet Food Preparation at Home
-
LEADING EDGE MATERIALS' INVESTOR UPDATE AND SIGNIFICANT ACTIVITIES
-
141,959 Orion Corporation A shares converted into B shares
-
LEADING EDGE MATERIALS' INVESTOR UPDATE AND SIGNIFICANT ACTIVITIES
-
Enterome presents positive Phase 2 interim results in relapsed/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics™ immunotherapy treatment at ICML
-
Antonio Filosa Announces New Stellantis Leadership Team on First Day as CEO
-
Antonio Filosa Announces New Stellantis Leadership Team on First Day as CEO
-
THEON secures c.€50 million new orders, directing revenue guidance to the upper range (€430 million)
-
AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease
-
New study published in Journal of Experimental Medicine reveals a CARMIL2 mutation with therapeutic antitumor potential
-
Caledonia Mining Corporation Plc: High Grade Drill Results at Blanket Mine
-
Opterion Health AG Appoints Industry Leaders Rice Powell and Mark Hahn to Board of Directors
-
NBPE - Transaction in Own Shares
-
Elis: Disclosure of trading in own shares occured from June 16 to June 20, 2025
-
New study published in Journal of Experimental Medicine reveals a CARMIL2 mutation with therapeutic antitumor potential
-
Lleida.net Wins First Latin American Tender for its Universal Signature Verification Certificate (USVC)
-
Shared Mobility Services to be Adopted by One Quarter of Global Population by 2028
-
Boyuan Capital (investment platform under Bosch Group) and Galbot Forged JV
-
Statement by the Texas Hemp Business Council on Governor Abbott’s Veto of SB3
-
35/2025・Trifork Group: Weekly report on share buyback
-
Transaction in Own Shares
-
Galapagos Appoints Aaron Cox as Chief Financial Officer
-
Readiness for further growth
-
SBC Medical Participated in 4 Investor Conferences in May and June 2025
-
Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A
-
Idorsia’s QUVIVIQ expands into China as Simcere receives NDA approval – Idorsia and Simcere update their licensing agreement
-
Start of Day Message
-
Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer
-
EPH European Property Holdings PLC Announces Change in Shareholder Structure
-
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma
-
Global Electronics Association Debuts; New Name Elevates IPC’s 70-Year Legacy as Voice of $6 Trillion Electronics Industry
-
ZA Miner Unveils 2025 Dogecoin & Ethereum Cloud Mining Event
-
ZA Miner Unveils 2025 Dogecoin & Ethereum Cloud Mining Event
-
Shareholders who own 3D Systems (NYSE: DDD) Should Contact Wolf Haldenstein
-
McLaren Health Care Data Breach Alert Issued By Wolf Haldenstein
-
PFMCrypto Launches Revolutionary XRP Mining Contracts, Igniting Market Enthusiasm
-
Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025
-
Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress


